Relapsed refractory acute myeloid leukemia
Conditions
Interventions
single arm:autologous CLL1/CD123-CAR-T
Sponsors
Dongguan Taixin Hospital
Eligibility
Sex/Gender
All
Age
1 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Acute myeloid leukemia (AML) diagnosed as CLL1/CD123-positive, relapsed during chemotherapy, or primary drug resistance, or complete hematologic remission after 1 course of hematologic relapse chemotherapy after withdrawal (standard reference NCCN, 2015.2); 2) Aged 1-70 years; 3) Patients >= 18 years old have self-knowledge ability and can sign informed and voluntary consent; the child's guardian or patient entrusted person joins the test after signing the informed and voluntary consent form. 4) The patient's main tissues and organs function well: a. Liver function: ALT/AST= 95%; d. Cardiac function: left ventricular ejection fraction (LVEF) >= 40%.
Exclusion criteria
Exclusion criteria: 1) intracranial hypertension or unconsciousness; 2) symptomatic heart failure or severe arrhythmia; 3) respiratory failure; 4) with other types of malignant tumors; 5) diffuse vascular internal coagulation; 6) serum creatinine and / or urea nitrogen >= 1.5 times the normal value; 7) sepsis or other uncontrollable infections; 8) Uncontrollable diabetes; 9) severe mental disorders; 10) Head MRI examination has obvious lesions in the skull; 11) Cerebrospinal fluid examination of leukemia cells > 20 / ul; 12) WHO physical status classification >= 3; 13) Organ transplant recipients; 14) Pregnant and lactating women. 15) Active hepatitis B/C virus: defined as DNA > 500 IU/ml; patients infected with HIV or syphilis; Patients who participate in clinical trials must meet the inclusion criteria and do not meet the exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactChunfu Li
Dongguan Taixin Hospital
Outcome results
None listed